Analysis of ANC recovery from a Phase III study of lipegfilgrastim versus pegfilgrastim in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

被引：0
|
作者：
Bondarenko, I. [1 ]
Bias, P. [2 ]
Elsaesser, R. [2 ]
Buchner, A. [2 ]
机构：
[1] Dnepropetrovsk Municipal Clin Hosp 4, Dnepropetrovsk, Ukraine
[2] Teva Ratiopharm, Ulm, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1961
引用
收藏
页码：S434 / S435
页数：2
相关论文
共 50 条
  • [21] Evaluation Of Electrocardiogram Parameters In Patients With Breast and Lung Cancer Treated With Chemotherapy and Lipegfilgrastim Or Pegfilgrastim
    Lammerich, Andreas
    Bondarenko, Igor
    Mueller, Udo
    BLOOD, 2013, 122 (21)
  • [22] PHASE II STUDY OF DOCETAXEL AND DOXORUBICIN COMBINATION AS NEOADJUVANT CHEMOTHERAPY IN OPERABLE BREAST CANCER PATIENTS
    Uddin, D.
    Hannan, A. A.
    Ahmed, I.
    ANNALS OF ONCOLOGY, 2010, 21 : 92 - 92
  • [23] Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer.: Results from the GEPARTRIO study
    von Minckwitz, G.
    Kuemmel, S.
    du Bois, A.
    Eiermann, W.
    Eidtmann, H.
    Gerber, B.
    Hilfrich, J.
    Huober, J.
    Costa, S. D.
    Jackisch, C.
    Grasshoff, S. -T.
    Vescia, S.
    Skacel, T.
    Loibl, S.
    Mehta, K. M.
    Kaufmann, M.
    ANNALS OF ONCOLOGY, 2008, 19 (02) : 292 - 298
  • [24] Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind, phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin
    Horvat-Karajz, K.
    Grecea, D.
    Smakal, M.
    Illes, A.
    Kahan, Z.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer:: results of the ERASME 3 study
    Cassier, Philippe A.
    Chabaud, Sylvie
    Trillet-Lenoir, Veronique
    Peaud, Pierre-Yves
    Tigaud, Jean-Dominique
    Cure, Herve
    Orfeuvre, Hubert
    Salles, Bruno
    Martin, Claude
    Jacquin, Jean-Philippe
    Agostini, Cecile
    Guastalla, Jean-Paul
    Perol, David
    Bachelot, Thomas
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (02) : 343 - 350
  • [26] A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Philippe A. Cassier
    Sylvie Chabaud
    Véronique Trillet-Lenoir
    Pierre-Yves Peaud
    Jean-Dominique Tigaud
    Hervé Cure
    Hubert Orfeuvre
    Bruno Salles
    Claude Martin
    Jean-Philippe Jacquin
    Cecile Agostini
    Jean-Paul Guastalla
    David Pérol
    Thomas Bachelot
    Breast Cancer Research and Treatment, 2008, 109 : 343 - 350
  • [27] Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: A preliminary report of the randomized phase III trial
    Aapro, M
    SEMINARS IN ONCOLOGY, 1998, 25 (05) : 7 - 11
  • [28] Economic analysis of pegfilgrastim in patients receiving cancer chemotherapy.
    Cosler, LE
    Eldar-Lissai, A
    Dale, DC
    Crawford, J
    Lyman, GH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 538S - 538S
  • [29] Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
    Kosaka, Yoshimasa
    Rai, Yoshiaki
    Masuda, Norikazu
    Takano, Toshimi
    Saeki, Toshiaki
    Nakamura, Seigo
    Shimazaki, Ryutaro
    Ito, Yoshinori
    Tokuda, Yutaka
    Tamura, Kazuo
    SUPPORTIVE CARE IN CANCER, 2015, 23 (04) : 1137 - 1143
  • [30] Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
    Yoshimasa Kosaka
    Yoshiaki Rai
    Norikazu Masuda
    Toshimi Takano
    Toshiaki Saeki
    Seigo Nakamura
    Ryutaro Shimazaki
    Yoshinori Ito
    Yutaka Tokuda
    Kazuo Tamura
    Supportive Care in Cancer, 2015, 23 : 1137 - 1143
12345